EPISODE · Feb 12, 2025 · 25 MIN
OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps
from WTR Healthcare Happenings · host Joe Brunetto
CEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.
What this episode covers
CEO Paul Romness and CBO Gerald Commisiong of OS Therapies join us on our WTR Biotech Spotlight podcast to talk about the OST-HER2 Phase 2b data in recurrent, liver metastatic osteosarcoma and what it could mean for patients with this aggressive cancer. We discuss the plan to approach the FDA and their confidence in a potential accelerated filing. Listen to learn more about OS Therapies and its cancer immunotherapy.
NOW PLAYING
OS Therapies CEO Paul Romness and CBO Gerald Commisiong Discuss Recent OST-HER2 Phase 2b Data and Next Steps
No transcript for this episode yet
Similar Episodes
No similar episodes found.